Brain Sciences (Jul 2022)

Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders

  • Alessandro Rodolico,
  • Carmen Concerto,
  • Alessia Ciancio,
  • Spyridon Siafis,
  • Laura Fusar-Poli,
  • Carla Benedicta Romano,
  • Elisa Vita Scavo,
  • Antonino Petralia,
  • Salvatore Salomone,
  • Maria Salvina Signorelli,
  • Stefan Leucht,
  • Eugenio Aguglia

DOI
https://doi.org/10.3390/brainsci12070891
Journal volume & issue
Vol. 12, no. 7
p. 891

Abstract

Read online

Antipsychotics are a class of psychotropic drugs that improve psychotic symptoms and reduce relapse risk. However, they may cause side effects (SE) that impact patients’ quality of life and psychosocial functioning. Therefore, there is a need for practical tools to identify them and possibly intervene. The objective of the present study was to translate into Italian the Glasgow Antipsychotic Side Effect Scale (GASS), which is suggested as the questionnaire of choice to collect SE reported by patients treated with antipsychotics. We administered the GASS and the Udvalg for Kliniske Undersøgelser (UKU) SE scale—which is considered the gold standard—to 100 stable patients with schizophrenia and bipolar spectrum disorders. We measured the structural validity, internal consistency, concurrent criterion validity, construct validity, and clinical feasibility. GASS was characterized by modest structural validity and good internal consistency. The binary correlations concerning the presence of specific symptoms investigated with the GASS and the UKU were strong or relatively strong for only half of them. The GASS total scale score was inversely related to patients’ quality of life and psychosocial functioning. The GASS is useful to briefly assess the burden of antipsychotic SE (~5 min) but is not optimal in identifying them.

Keywords